Agenda

Melissa Gong Mitchell is Executive Director of the Global Coalition on Aging, the leading business voice on aging policy and strategy. She also serves as Managing Director at High Lantern Group, a strategic communications consulting firm. GCOA uniquely brings together global corporations across industry sectors to promote good public policy and market-based solutions centered on healthy and active aging.  In her role, Melissa is responsible for the operations and management of the coalition, internal and external communication strategies, and member and stakeholder outreach and development, including fostering relationships and aligning partners across industry, academia, the NGO community, advocacy organizations, governments and global institutions. Melissa has spoken around the world about the opportunities of the aging mega-trend and the role of business in leveraging aging for economic growth. She has served as a member of the Professions Working Group that advises the Age-friendly New York City Commission and as a member of the Benefit Committee of the Skin Cancer Foundation.

Alexandra Bhatti is a public health attorney with a decade of diverse vaccine programmatic and policy experience across the government and private sector. She is currently Director of US Vaccine Public Policy at Merck & Co. Inc, where she leads US state and federal vaccine policy development and research as well as federal vaccine policy advocacy to advance evidence-based policy solutions that can help achieve and sustain high vaccination rates.   She concurrently has served as faculty at Arizona State University in the School for the Science of Healthcare Delivery over the last 7 years. Prior to Merck, Ms. Bhatti was a public health attorney at the Centers for Disease Control and Prevention where she led vaccination law research.  Her roots are in state public health where she was previously  a manager within the Arizona Department of Health, Immunization Program Office as well as a Senior Public Health Scientist within their state laboratory. 

Dr Michael Devoy is the Executive Vice President for Medical Affairs and Pharmacovigilance for the Pharmaceuticals Division at Bayer AG. He is also the Chief Medical Officer of Bayer AG. Dr Devoy joined the former Schering AG in 2005 as Senior Vice President of Global Medical Development and was appointed to his current position in 2014.

Dr Devoy studied Medicine and Pharmacology at University College London and graduated with a Bachelor of Medicine/Bachelor of Surgery (MB, BS, graduated with honors) and BSc in Pharmacology. He is a member of the Royal College of Physicians in London. He is also an elected member of the Board of Directors of the Drug Information Association (DIA).

Dr Devoy has extensive experience across Clinical Development and International Medical Affairs. His career in the pharmaceutical industry began when he joined Glaxo Group Research in Clinical Pharmacology.

Eric is a Senior Health Economist leading the OECD’s work in Digital Health, bringing together policy guidance for responsible analytics, integrated data, and digital tools. In that role, he is accountable for supporting digital health policy that enables digital shifts from facility-centric to person-centric healthcare. Person-centric healthcare will provide timely and easy access to quality data for individuals and their providers to optimize the use of data for information, insights, and impact while ensuring protections are in place. Eric had been called a data guy with personality and has an unusual passion for bringing digital transformation in health to life.

Prof. Mario Barbagallo, MD, PhD, is Full Professor of Internal Medicine and Geriatrics; Director of the Department of Medicine, University Hospital of Palermo; Director of the Post-graduate program in Geriatrics; 
President of IAGG-ER (International association of Geriatrics-European Region). 
Member of the Superior Council of the Italian Minister of Health. 
He is included in the list of the Top Italian Scientists (www.topitalianscientists.org). 
He previously worked in Parma and in Rome where he obtained the PhD, and in the US (at the CornellUniversity Medical Center, NY, NY, USA, and as a Fulbright Scholar and Visiting Professor at Wayne State University, Detroit, MI, USA). 
He is an expert of clinical, social and biological problems related aging, and to the prevention and treatment ofaging-related diseases.
He is member of numerous national and international scientific societies and appreciated speaker in Italy and abroad and Author of over 500 publications in scientific journals.

Dr. Jian Yang, Associate VP, Senior Director Digital Health, Eli Lilly and Co
A physician by training with extensive experience in R&D, medical and commercial areas, Dr. Yang has keen understanding of the issues, challenges and opportunities in healthcare system and pharmaceutical industry. Dr. Yang is passionate about leveraging digital technology to drive healthcare transformation and deliver better outcome. He is a result driven leader with global vision and career footprints in many countries - US, China, Japan and Singapore.

Currently, Dr. Yang leads teams that are composed of physicians, biomedical engineers and data scientists to develop Lilly’s capabilities in Digital Health across therapeutic areas. He has leadership oversight for digital biomarkers (dBMs), behavioral coaching and digital therapies. 

In his previous roles, Dr. Yang was responsible for Eli Lilly's Connected Care technology portfolio including software as a medical device, cloud services and big data analytics. He had responsibility in driving commercial transformation for Business Units through holistic digital strategies and technology innovation. He had also established Integrated Genomics Platform for Cancer Research at Lilly Research Labs.

Before joining Lilly, Dr. Yang led the effort in designing and managing HIPPA compliant medical informatics system for medical and epidemiological researches in collaboration with WHO and US Centers for Disease Control and Prevention.